Itch Relief Breakthrough: Sumatriptan's Surprising Role in Soothing Skin
"New research reveals how a common migraine medication could hold the key to calming chronic itch, offering hope for those seeking alternative treatments."
Chronic itch, or pruritus, is more than just a nuisance; it's a debilitating symptom that significantly impacts the quality of life for many. Traditional treatments, like antihistamines, often fall short, leaving sufferers searching for effective relief. Scientists have been working hard to find out what causes itch in order to provide alternative treatments.
One area of growing interest is histamine-independent itch, which doesn't respond to common antihistamines. A common research model utilizes chloroquine (CQ) to induce itch. Recent studies suggest that nitric oxide (NO) plays a crucial role in this type of itch, making it a potential target for new therapies.
Now, a new study sheds light on the potential of sumatriptan, a medication commonly used to treat migraines and cluster headaches, in alleviating chloroquine-induced itch. The findings reveal its involvement in the nitric oxide pathway, offering a promising avenue for novel anti-itch treatments.
Usage Data and Emerging Itch Research
The ClinCalc DrugStats Database reports U.S. sumatriptan drug-usage statistics from 2014 through 2024, covering products and synonyms such as Imitrex, Alsuma, Tosymra, and Zembrace Symtouch. Sumatriptan is primarily identified as a serotonin-1B and serotonin-1D receptor agonist, while emerging research has examined its possible role in reducing chloroquine-induced scratching. A study on serotonin-induced itch reported that 5-HT1B/1D receptor agonists may be useful for some pathologic itch conditions involving impaired serotonergic signaling.
Why Chronic Itch Requires Tailored Care
Management of chronic pruritus depends on identifying its underlying cause, which may fall into six separate etiologic categories. Reviews describe treatment algorithms and therapeutic approaches for refractory chronic pruritus associated with inflammatory disorders, chronic prurigo, chronic kidney disease, and cholestatic pruritus. Chronic pruritus is generally defined as itch lasting more than six weeks and can arise from systemic disease, malignancy, neuropathic conditions, or dermatoses, making a single universal treatment approach inappropriate.
From Migraine Therapy to Repurposing
Sumatriptan was the first-in-class selective serotonin 5-HT1B/1D receptor agonist, developed by researchers at Glaxo, now GlaxoSmithKline, during the 1980s. Its development revolutionized the acute treatment of migraine and cluster headaches and led to the availability of additional triptans. The discovery also helped establish migraine as an organic disease rather than an imagined condition, according to a historical account of the drug's development.
How Sumatriptan Calms the Itch: Targeting the Nitric Oxide Pathway
The research, led by Prof. Ahmad Reza Dehpour and colleagues, investigated the effect of sumatriptan on CQ-induced scratching in mice. They focused on the rostral back model of itch, where chloroquine is injected intradermally to trigger scratching behavior. The study evaluated how sumatriptan, alone and in combination with other compounds, affected this scratching.
- Sumatriptan Reduces Scratching: Both intraperitoneal (IP) and intradermal (ID) administration of sumatriptan significantly reduced CQ-induced scratching in mice.
- Reversal by GR-127935: The anti-pruritic effect of sumatriptan was reversed by GR-127935, a selective 5-HTR1b and 5-HTR1d antagonist, highlighting the involvement of these receptors.
- Combined Action with L-NAME: Combining sub-effective doses of sumatriptan and L-NAME, a non-selective nitric oxide synthase inhibitor, further decreased scratching behavior.
- Reduced Nitrite Levels: Sumatriptan significantly reduced intradermal nitrite levels, indicating its impact on the nitric oxide pathway.
Nitric Oxide and Drug Repurposing
Recent reviews frame sumatriptan research within the broader field of drug repurposing, which validates existing molecular targets and evaluates known compounds for new therapeutic uses. A systematic review reports that activation of the nitric oxide pathway aggravates chloroquine-induced and other types of pruritus. Another study attributes sumatriptan's therapeutic effects in various pathological conditions to inhibition of nitric oxide signaling, supporting further investigation of this mechanism while not establishing sumatriptan as an approved itch treatment.
The Future of Itch Relief: New Therapeutic Targets
This research opens new avenues for developing targeted treatments for chronic itch. By understanding the role of sumatriptan and the nitric oxide pathway, scientists can explore new therapeutic interventions that provide more effective and lasting relief.
Patients' Experience of Chronic Urticaria
The Urticaria Voices studies examine the real-world experience, treatment, and management needs of people living with chronic spontaneous urticaria and the perspectives of physicians treating them. Chronic spontaneous urticaria is characterized by itchy wheals or hives and/or angioedema lasting longer than six weeks. The research aims to clarify the disease journey, treatment patterns, outcomes, and gaps between patient needs and clinical care.
While the study focused on chloroquine-induced itch in mice, the findings have broader implications for understanding and treating other types of histamine-independent itch. Further research is needed to determine the effectiveness of triptans in treating pruritic diseases in humans.
The discovery may provide insight for development of new target therapeutics to treat CQ-induced itch as well as better understanding of pharmacological interaction of this phenomenon. However, the potency of drugs to reduce itch in human is difficult to be interpreted by mouse models due to species differences. Thus, further studies will be significant to clarify the role for triptans in pruritic diseases in humans.